| Literature DB >> 33802821 |
Alexander B Shcherbakov1, Vladimir V Reukov2, Alexander V Yakimansky3, Elena L Krasnopeeva3, Olga S Ivanova4, Anton L Popov4,5, Vladimir K Ivanov4.
Abstract
The development of advanced composite biomaterials combining the versatility and biodegradability of polymers and the unique characteristics of metal oxide nanoparticles unveils new horizons in emerging biomedical applications, including tissue regeneration, drug delivery and gene therapy, theranostics and medical imaging. Nanocrystalline cerium(IV) oxide, or nanoceria, stands out from a crowd of other metal oxides as being a truly unique material, showing great potential in biomedicine due to its low systemic toxicity and numerous beneficial effects on living systems. The combination of nanoceria with new generations of biomedical polymers, such as PolyHEMA (poly(2-hydroxyethyl methacrylate)-based hydrogels, electrospun nanofibrous polycaprolactone or natural-based chitosan or cellulose, helps to expand the prospective area of applications by facilitating their bioavailability and averting potential negative effects. This review describes recent advances in biomedical polymeric material practices, highlights up-to-the-minute cerium oxide nanoparticle applications, as well as polymer-nanoceria composites, and aims to address the question: how can nanoceria enhance the biomedical potential of modern polymeric materials?Entities:
Keywords: COVID-19; biocomposites; hybrid materials; nanomaterials; therapy
Year: 2021 PMID: 33802821 PMCID: PMC8002506 DOI: 10.3390/polym13060924
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Different dimensionality classes of biomedical polymers.
Composition and biochemical applications of ceria-polymeric composites.
| Polymer | CeNPs Characteristics | Nanocomposite Products | Applications | Results | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Cellulose | Cubic CeNPs, 3.2–32 nm; 300 mL of water containing 1- or 5-mM cerium nitrate and 1% cellulose was used as a precursor. | Three-dimensional scaffolds | Tissue engineering | Nanobiocomposites are not cytotoxic to HeLa cells at a concentration as high as >1 mg·mL−1 and scavenge ROS. | [ |
| PCL | Size 9–16 nm; 0.5%, 1%, 2% and 3%. | Electrospun fiber scaffolds | Tissue engineering | In vitro (MSC): higher cell adhesion and proliferation were evident relative to bare PCL. | [ |
| PL | CeNPs having different Ce4+ and Ce3+ ratios | Scaffold/artificial-niche | Tissue engineering | Mesenchymal stem (MSCs) and osteoblast-like (MG63) cells were cultured on PL/CNP surfaces with Ce4+- or Ce3+-enriched regions. Despite cell type (MSCs and MG63 cells), different cerium valence state regions promoted or inhibited cell spreading, migration or adhesion behavior, resulting in rapid or slow cell proliferation. | [ |
| PL | ~5 nm, oleylamine-capped CeNPs, up to 10 wt%: cancellous bone impregnated by PL + CeNPs | Scaffolds | Bone tissue engineering | In vitro: coculture of endothelial progenitor cells and MSC on scaffold supplemented with CeNPs showed the improvement of cell viability and the differentiation process for endothelial progenitor cells. | [ |
| Gelatin | CeNPs by AlfaAesar as a 20% aqueous solution at acidic pH, with nominal size <5 nm. 15% gelatin and 1 mg/mL CeNPs were used as a precursor, GPTMS as a cross-linker | Electrospun fiber scaffolds | Neuronal tissue engineering and regenerative medicine | The scaffolds demonstrate strong antioxidant properties and beneficial multi-cue effects in terms of neurite development and alignment on neuron-like SH-SY5Y cells. | [ |
| Gelatin/alginate | Mean diameter 35.5 nm, zeta potential −12.35 ± 1.39 mV; 100 μg/mL, 500 μg/mL and 1000 μg/mL | Scaffolds | Bone regeneration | Highest mesenchymal stem cells (MSCs) proliferation rate was observed for 1000 μg/mL CeNPs scaffolds; application of the scaffolds resulted in enhanced osteogenic differentiation of MSCs, as well as free radical scavenging. | [ |
| POC | <25 nm particle size (Sigma-Aldrich), 10 or 20 wt% relative to POC | Scaffolds | Bone tissue regeneration | Scaffolds are biocompatible and supported cell attachment, proliferation, mineralization and infiltration. They possess protective properties against ROS via the reduction in cytotoxicity, improving mineralization of osteoblast cells in vitro. Cells are able to infiltrate through the scaffolds, the surrounding tissues elicit a minimal immune response. Nanocomposite scaffold system is capable of supporting bone-remodeling processes while providing a protective free radical scavenging effect. | [ |
| PLGA | CeNPs size ~5 nm; 20 mg of CeNPs in 200 mg of PLGA | Microparticles and scaffolds | CeNPs delivery, tissue engineering including bone remodeling and regeneration | The release kinetics of CNPs from PLGA matrix was investigated under acidic, basic and near-neutral pHs. Superoxide dismutase (SOD) mimetic activity was retained in released CNPs for a long period of time (∼90 days). PLGA encapsulated CeNPs showed excellent biocompatibility. | [ |
|
| |||||
| Chitosan/PVA | zeta potential 50 mV, ∼5 nm in diameter, 0.5% and 1% | Hydrogels | Wound healing | Enhanced cell compatibility and survival, antibacterial activity against MRSA | [ |
| PHBV | 8.6 ± 3.8 nm in diameter (TEM); 0.5%, 1%, 2% and 4% | Electrospun membranes | Diabetic wound healing | In vitro: For less than 1% w/w of CeNPs content, human mammary epithelial cells adhered parallel to individual fibers; for higher CeNPs content, cells started to flatten and spread over the fibers. | [ |
| Chitosan/cellulose acetate | <25 nm particle size (Sigma-Aldrich), 0.1% and 1% | Films | Wound dressing | Good water vapour transmission rates (WVTR) and water vapour permeability (WVP) values, antibacterial behavior for | [ |
| PCL/gelatin (1:1) | <25 nm particle size, 1.5, 3 and 6% | Electrospun films | Wound dressing | In vitro: 1.5% CeNPs exhibited the highest cell proliferation with L929 cells. | [ |
| PCL/gelatin (1:1) | ~42 nm in size, zeta potential 30.8 mV. The nanofibers were fabricated from a polymer solution of 10% | Electrospun fibers | Wound healing | Enhanced proliferation of 3T3-L1 cells (by ~48%), ROS scavenging ability, three-fold increase in the viability and proliferation of cells. | [ |
| Gelatin | 2.5–6.5 nm in size. From 50 μg/mL to 500 μg/mL dispersed into gelatin solution (5%, w/v), optimal concentration 250 μg/mL | Composite hydrogels | Wound healing | In vitro: 250 μg/mL provided 86 ± 1.4% cell viability and increased bound water content (swelling ratio was three-fold to that of native gelatin). | [ |
| GelMA-DOPA | 10–30 nm in size (US Research Nanomaterials), 100.0 μg/mL | Sprayable hydrogel | Wound dressing | Hydrogel provided a multifunctional wound dressing with desired antimicrobial, ROS-scavenging, adhesive, and degradative properties both in vitro and in vivo. | [ |
| PCL | Mesoporous CeO2 nanorods, | Nanomembranes | Cutaneous wound healing | High antimicrobial activity against | [ |
| Zwitterionic cryogel of CBMA or SBMA and HEMA | CeNPs size range of 3–5 nm; 68 μL of aqueous 36.6 μM FITC-labelled CeNPs were added to 250 μL of gel prior to polymerization | Injectable gels | Wound healing | The gels speed up diabetic wound healing and significantly reduce inflammation. | [ |
| Gelatin/oxidized dextran | Particle size < 50 nm, 430 ug in 1 mL of gel | Hydrogel dressings | Wound healing | Prolonged drug (curcumin) release (∼63% in 108 h), accelerated cell migration, significant antioxidant and anti-inflammatory activity in vivo (∼39%). | [ |
| PAA/curcumin | 220 by 30–75 nm CeNPs; 0.1 mM, 0.2 mM and 0.4 mM | Hydrogel dressings | Scarless healing of injury | In a full-thickness acute wound healing model of rat, a single application of dressing demonstrated higher wound healing efficacy (78%) and negligible scarring in 7 days. Enhanced cell proliferation, higher collagen content, advanced wound maturity, re-epithelialization and granulation tissue formation were observed. | [ |
|
| |||||
| PArg/DS | Citrate-stabilized CeNPs, 4–7 nm, ζ-potential ~–40 mV | LbL microcapsules | Drug delivery | CeNPs provide “active” protection of loaded content (luciferase enzyme) against hydrogen peroxide and “passive” shielding against small molecules. | [ |
| Alginate/Chitosan | Citrate-stabilized CeNPs, diameter ~5 nm, ζ-potential −16.99 ± 2.72 mV | LbL-coated silicone containers | Drug delivery | CeNPs functionality prevents burst blowout of model drug (curcumin). | [ |
| PArg/DS | Citrate-stabilized CeNPs, 2–2.5 nm, negative ζ-potential | LbL microcapsules | Drug delivery, radioprotection | CeNPs microcapsules provide enhanced cellular internalization and good radioprotection. | [ |
| PEG/PLGA | Mostly uniform spherical CeNPs 5–10 nm in size | ~40 nm nanoparticles | Cerebral ischemic therapy, brain targeted drug delivery | 10 mg/kg concentration resulted in 60–78% lessening of focal ischemia in middle cerebral artery occlusion model of brain stroke. | [ |
| PLGA | Diameter of 2–3 nm; 1 μM of CeNPs was suspended in 2.5% aqueous PVA solution containing 40 mg of PLGA as a precursor | Microparticles | CeNPs and drugs co-delivery | PLGA is a suitable encapsulating carrier for simultaneous delivery of nanoceria and SOD. This combination effectively reduces oxidative stress in vitro. | [ |
|
| |||||
| PVA | 0.5, 1.5 and 3% | Electrospun mats of nanocomposite hydrogels | Various biomedical applications | Better platelet adhesion and accelerated wound healing | [ |
| TPU | CeNPs size ∼60 nm; 0.1–0.7 wt% | Various biomedical applications | Enhanced blood compatibility, cell viability, chemical resistance, mechanical and thermal properties of TPU. | [ | |
| Alginate | Dextran-coated CeNPs, 2.7–9 nm radius (23.8% polydispersity); 0.1, 1.0 and 10 mM CeNPs in hydrogel. | Composite hydrogel microcapsules | Cellular transplantation | Cytoprotection of encapsulated insulin-producing MIN6 beta cells from free radical attack. No cytotoxicity up to 10 mM CeNPs. | [ |
| PLGA | 5 to 8 nm in size; 5, 10 and 20 wt% | Hybrid 2D polymeric-ceramic biosupports | Regenerative medicine | Better murine derived cardiac and mesenchymal stem cells’ proliferative activity is observed for CeO2 polymer composites with respect to either TiO2-filled or unfilled PLGA films. | [ |
| PL/Gelatin | Polyhedral nanoparticles 5–10 nm in size; 0.25%,0.5% and 1% | Electrospun fibro-porous membranes | Scaffolds for angiogenesis | Good hydrophilicity, water absorption and improved mechanical properties; scaffolds were shown to be biocompatible both in vitro (somatic hybrid endothelial cells) and in vivo (chick embryo angiogenesis assay); pro-angiogenic activities of the scaffolds are comparable to VEGF. | [ |
| Alginate | Particle size < 5 nm, 20 wt% in H2O, pH~4 (Sigma Aldrich) | LbL-coated alginate microbeads | Biomedical implants, including cellular transplantation | 12 layers of CeNPs/alginate provided complete protection to the entrapped beta cells from exposure to 100 μM H2O2, with no significant changes in metabolic activity, oxidant capacity or insulin secretion dynamics, when compared to untreated control. | [ |
| PU with CA/Zein | CeO2 nanofibers were composed of nanoparticles ca.10–20 nm in size; 10% | Electrospun fiber mats | Antibacterial smart material | Composite nanofibers demonstrated notable toxicity against | [ |
CA = Cellulose acetate; CBMA = 3-[[2-(Methacryloyloxy)ethyl] dimethylammonium] propionate; CeNPs = Ceria nanoparticles; GPTMS = (3-glycidyloxypropyl) trimethoxysilane; DOPA = dopamine; HEMA = 2-Hydroxyethyl methacrylate; GelMA = gelatin methacryloyl; PAA = Poly(acrylamide); PArg = poly-L-arginine; DS = dextran sulfate; PCL = Poly(ε-caprolactone); PEG = Polyethylene glycol; PHBV = Poly(3-hydroxybutyrate-co-3-hydroxyvalerate); PL = Poly-(l-lactide); PLGA = Poly(lactide-co-glycolide); POC = Poly(1,8-octanediol-co-citrate); PU = Polyurethane; PVA = Polyvinyl alcohol; SBMA = [2-(methacryloloxy) ethyl] dimethyl-(3-sulfopropyl) ammonium hydroxide; TMC = Trimethyl chitosan; TPU = Thermoplastic polyurethane.
Figure 2Biomedical applications of polymeric electrospun fibers.
Figure 3Applications of hydrogels in biomedicine.
Figure 4Classification of microencapsulation techniques used in preparation of medicinal products.
Figure 5Smart release stimuli (single/dual/multi) for advanced drug delivery via microencapsulation.
Figure 6Cerium oxide nanoparticles modified with methacrylate phosphate for possible use as a filler for curing dental polymer compositions.
Figure 7CeNPs can provide additional advantages for contact lens polymeric materials.
Improvements to the properties of ceria nanoparticles and polymers by the development of ceria-polymeric composites.
|
| |
| Physical, chemical | Decreased CeNPs solubility and free Ce-ions leakage; |
| Biomedical | Decreased toxicity: |
|
| |
| Physical | Tunable mechanical, thermal and electric properties; |
| Chemical, | Enhanced chemical resistance, decreased erosion/corrosion, prolonged durability; |
| Biomedical | Enhanced cell adhesion, proliferation, migration and tissue repair; |